Oligodendroglioma classification: Difference between revisions
Jump to navigation
Jump to search
(Created page with "fcasfvas") |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Oligodendroglioma}} | |||
{{CMG}}{{AE}}{{SR}} | |||
==Overview== | |||
==Classification== | |||
According to the WHO classification of brain tumors, oligodendroglial tumors are separated into oligodendrogliomas WHO grade II (OII), anaplastic oligodendrogliomas WHO grade III (OIII), oligoastrocytomas WHO grade II (OAII), anaplastic oligoastrocytomas WHO grade III (OAIII), and glioblastomas with oligodendroglioma component WHO grade IV (GBMo) (Louis et al. 2007).<ref name="pmid19322536">{{cite journal| author=Hartmann C, von Deimling A| title=Molecular pathology of oligodendroglial tumors. | journal=Recent Results Cancer Res | year= 2009 | volume= 171 | issue= | pages= 25-49 | pmid=19322536 | doi=10.1007/978-3-540-31206-2_2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19322536 }} </ref> | |||
==Reference== | |||
{{reflist|2}} | |||
Revision as of 20:41, 6 October 2015
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma classification On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma classification |
|
Risk calculators and risk factors for Oligodendroglioma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Classification
According to the WHO classification of brain tumors, oligodendroglial tumors are separated into oligodendrogliomas WHO grade II (OII), anaplastic oligodendrogliomas WHO grade III (OIII), oligoastrocytomas WHO grade II (OAII), anaplastic oligoastrocytomas WHO grade III (OAIII), and glioblastomas with oligodendroglioma component WHO grade IV (GBMo) (Louis et al. 2007).[1]
Reference
- ↑ Hartmann C, von Deimling A (2009). "Molecular pathology of oligodendroglial tumors". Recent Results Cancer Res. 171: 25–49. doi:10.1007/978-3-540-31206-2_2. PMID 19322536.